LncRNA FGD5-AS1 enhances the proliferation and stemness of hepatocellular carcinoma cells through targeting miR-223 and regulating the expression of ECT2 and FAT1.
ECT2
FDG5-AS1
hepatocellular carcinoma
miR-223
proliferation
stemness
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
14
03
2022
received:
22
06
2021
accepted:
21
03
2022
pubmed:
3
4
2022
medline:
3
4
2022
entrez:
2
4
2022
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is common and causes many deaths worldwide. The aim of this study is to explore the mechanism by which long non-coding RNA FGD5-AS1 regulates HCC cell proliferation and stemness. Tumor and normal adjacent tissues were harvested from HCC patients. Real-time quantitative reverse transcription-PCR was applied to examine the expression of FGD5-AS1, miR-223, Epithelial cell transforming sequence 2 (ECT2) and FAT1. The protein levels of ECT2, FAT1, proliferating cell nuclear antigen (PCNA), OCT4, CD133 and CD90 were analyzed by western blot. The localization of FGD5-AS1 was examined by Fluorescence in situ hybridization. Cell proliferation was analyzed with CCK-8 and colony formation assays. Spheroid formation was used for analyzing cell stemness. Gene interaction was examined by RNA immunoprecipitation and luciferase activity assays. A subcutaneous xenograft mouse model was established to analyze HCC growth and stemness in vivo. Immunohistochemistry staining was used to analyze the expression PCNA and OCT4 in subcutaneous tumors. FGD5-AS1 was upregulated in HCC and its high expression indicated poor prognosis of patients. High expression of FGD5-AS1 enhanced HCC cell proliferation and stemness. Knockdown of FGD5-AS1 restrained tumor growth and stemness in mice. FGD5-AS1 directly sponged miR-223 and promoted the expression of ECT2 and FAT1 in HCC. Both knockdown of miR-223 and overexpression of ECT2 and FAT1 reversed FGD5-AS1 silencing-mediated suppression of HCC cell proliferation and stemness. FGD5-AS1 directly sponged miR-223 and promoted the expression of ECT2 and FAT1 in HCC, thus enhancing HCC cell proliferation and stemness. Our study identifies potential prognostic biomarkers and therapeutic targets for HCC.
Types de publication
Journal Article
Langues
eng
Pagination
614-629Informations de copyright
© 2022 Japan Society of Hepatology.
Références
Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016;2:16018.
Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, et al. Rupture of hepatocellular carcinoma: a review of literature. J Clin Exp Hepatol Mar-Apr. 2019;9:245-56.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet Mar 31. 2018;391:1301-14.
Villanueva A. Hepatocellular carcinoma. N Engl J Med Apr 11. 2019;380:1450-62.
Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol Jun. 2019;234:8381-95.
Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, et al. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918816287.
Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol Aug 30. 2016;9:74.
Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics Mar. 2013;193:651-69.
Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell Nov 14. 2019;179:1033-55.
Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res Aug 1. 2017;77:3965-81.
Fan Y, Li H, Yu Z, Dong W, Cui X, Ma J, et al. Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1. Biosci Rep Jan 31. 2020;40.
Wu L, Zhu X, Song Z, Guo M, Liang J, Yan D. FGD5-AS1 facilitates glioblastoma progression by activation of Wnt/beta-catenin signaling via regulating miR-129-5p/HNRNPK axis. Life Sci Sep 1. 2020;256:117998.
Gao Y, Xie M, Guo Y, Yang Q, Hu S, Li Z. Long non-coding RNA FGD5-AS1 regulates cancer cell proliferation and chemoresistance in gastric cancer through miR-153-3p/CITED2 axis. Front Genet. 2020;11:715.
Li D, Jiang X, Zhang X, Cao G, Wang D, Chen Z. Long noncoding RNA FGD5-AS1 promotes colorectal cancer cell proliferation, migration, and invasion through upregulating CDCA7 via sponging miR-302e. In Vitro Cell Dev Biol Anim Sep. 2019;55:577-85.
Yan H, Wang Q, Shen Q, Li Z, Tian J, Jiang Q, et al. Identification of potential transcription factors, long noncoding RNAs, and microRNAs associated with hepatocellular carcinoma. J Cancer Res Therapeut Sep. 2018;14:S622-S7.
Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA interactions. Methods Mol Biol. 2016;1402:271-86.
Lopez-Urrutia E, Bustamante Montes LP, Ladron de Guevara Cervantes D, Perez-Plasencia C, Campos-Parra AD. Crosstalk between long non-coding RNAs, Micro-RNAs and mRNAs: deciphering molecular mechanisms of master regulators in cancer. Front Oncol. 2019;9:669.
Zhang XQ, Song LH, Feng SJ, Dai XM. LncRNA FGD5-AS1 acts as a competing endogenous RNA for miRNA-223 to lessen oxygen-glucose deprivation and simulated reperfusion (OGD/R)-induced neurons injury. Folia Neuropathol. 2019;57:357-65.
Ye D, Zhang T, Lou G, Liu Y. Role of miR-223 in the pathophysiology of liver diseases. Exp Mol Med Sep 26. 2018;50:128.
Wang X, Tong Z, Liu H. MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells. OncoTargets Ther. 2019;12:7675-84.
Xu J, Wang B, Liu ZT, Lai MC, Zhang ML, Zheng SS. miR-223-3p regulating the occurrence and development of liver cancer cells by targeting FAT1 gene. Math Biosci Eng Dec 3. 2019;17:1534-47.
Yu Y, Cai O, Wu P, Tan S. MiR-490-5p inhibits the stemness of hepatocellular carcinoma cells by targeting ECT2. J Cell Biochem Jan. 2019;120:967-76.
Srivastava C, Irshad K, Dikshit B, Chattopadhyay P, Sarkar C, Gupta DK, et al. FAT1 modulates EMT and stemness genes expression in hypoxic glioblastoma. Int J Cancer Feb 15. 2018;142:805-12.
Fields AP, Justilien V. The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. Adv Enzym Regul. 2010;50:190-200.
Chen M, Sun X, Wang Y, Ling K, Chen C, Cai X, et al. FAT1 inhibits the proliferation and metastasis of cervical cancer cells by binding beta-catenin. Int J Clin Exp Pathol. 2019;12:3807-18.
Ren Z, Ma X, Duan Z, Chen X. Diagnosis, therapy, and prognosis for hepatocellular carcinoma. Anal Cell Pathol. 2020;2020:8157406.
Fu J, Cai H, Wu Y, Fang S, Wang D. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene Sep 10. 2020;755:144886.
Liu L, Zhan Y, Huang Y, Huang L. LncRNA FGD5-AS1 can be predicted as therapeutic target in oral cancer. J Oral Pathol Med Mar. 2020;49:243-52.
Gao J, Zhang Z, Su H, Zong L, Li Y. Long noncoding RNA FGD5-AS1 acts as a competing endogenous RNA on microRNA-383 to enhance the malignant characteristics of esophageal squamous cell carcinoma by increasing SP1 expression. Cancer Manag Res. 2020;12:2265-78.
Su D, Ji Z, Xue P, Guo S, Jia Q, Sun H. Long-Noncoding RNA FGD5-AS1 enhances the viability, migration, and invasion of glioblastoma cells by regulating the miR-103a-3p/TPD52 axis. Cancer Manag Res. 2020;12:6317-29.
Lv J, Li Q, Ma R, Wang Z, Yu Y, Liu H, et al. Long noncoding RNA FGD5-AS1 knockdown decrease viability, migration, and invasion of non-small cell lung cancer (NSCLC) cells by regulating the MicroRNA-944/MACC1 axis. Technol Cancer Res Treat Jan-Dec. 2021;20:1533033821990090.
Lo RC, Leung CO, Chan KK, Ho DW-H, Wong C-M, Lee TK-W, et al. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing dishevelled-3 and activating Wnt/beta-catenin pathway. Cell Death Differ Aug. 2018;25:1426-41.
Lu X, Zhou C, Li R, Liang Z, Zhai W, Zhao L, et al. Critical role for the long non-coding RNA AFAP1-AS1 in the proliferation and metastasis of hepatocellular carcinoma. Tumour biol Jul. 2016;37:9699-707.
Wang F, Xie C, Zhao W, Deng Z, Yang H, Fang Q. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Clin Exp Med Feb. 2017;17:33-43.
Yuan SX, Wang J, Yang F, Tao Q-f, Zhang J, Wang L-l, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology Feb. 2016;63:499-511.
Aichen Z, Kun W, Xiaochun S, Lingling T. LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p. Apoptosis Jun. 2021;26:348-60.
Ge C, Dong J, Chu Y, Cao S, Zhang J, Wei J. LncRNA FGD5-AS1 promotes tumor growth by regulating MCL1 via sponging miR-153-3p in oral cancer. Aging Jul 16. 2020;12:14355-64.
Chai B, Guo Y, Cui X, Liu J, Suo Y, Dou Z, et al. MiR-223-3p promotes the proliferation, invasion and migration of colon cancer cells by negative regulating PRDM1. American journal of translational research. 2019;11:4516-23.
Kurozumi A, Goto Y, Matsushita R, Fukumoto I, Kato M, Nishikawa R, et al. Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. Cancer Sci Jan. 2016;107:84-94.